Korean J Urol Oncol.  2016 Aug;14(2):47-53. 10.22465/kjuo.2016.14.2.47.

Chemotherapy in Advanced Urothelial Carcinoma

Affiliations
  • 1Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. doctork@knu.ac.kr

Abstract

Despite recent advances in the management of a wide variety of solid tumors, the outcomes for patients with advanced urothelial carcinoma remain relatively poor. Cisplatin-based combination chemotherapy remains the standard of care for first-line systemic treatment of advanced urothelial carcinoma and for more than 10 years there have been no other Korean health insurance system-approved treatment options available for these patients. In this review article, we summarize the current state of chemotherapeutic agents, used either alone or in combination with other chemotherapy in advanced urothelial carcinoma. Our discussion focuses on the new agents for the cisplatin ineligible patients, including carboplatin, gemcitabine, paclitaxel, docetaxel and pemetrexed. Moreover, we addressed that neoadjuvant chemotherapy was supported in the patients planning radical cystectomy as an optimal treatment option by qualified studies.

Keyword

Carcinoma; Transitional Cell Carcinoma; Chemotherapy

MeSH Terms

Carboplatin
Carcinoma, Transitional Cell
Cisplatin
Cystectomy
Drug Therapy*
Drug Therapy, Combination
Humans
Insurance, Health
Paclitaxel
Pemetrexed
Standard of Care
Carboplatin
Cisplatin
Paclitaxel
Pemetrexed
Full Text Links
  • KJUO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr